Davenport & Co’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-738
| Closed | -$4.42K | – | 1147 |
|
|
2024
Q4 | $4.42K | Sell |
738
-315
| -30% | -$1.89K | ﹤0.01% | 1119 |
|
|
2024
Q3 | $10.3K | Sell |
1,053
-272
| -21% | -$2.66K | ﹤0.01% | 1110 |
|
|
2024
Q2 | $27.1K | Sell |
1,325
-824
| -38% | -$16.9K | ﹤0.01% | 1078 |
|
|
2024
Q1 | $97K | Sell |
2,149
-63
| -3% | -$2.84K | ﹤0.01% | 1064 |
|
|
2023
Q4 | $104K | Sell |
2,212
-1,632
| -42% | -$77K | ﹤0.01% | 1020 |
|
|
2023
Q3 | $156K | Buy |
3,844
+112
| +3% | +$4.53K | ﹤0.01% | 991 |
|
|
2023
Q2 | $398K | Sell |
3,732
-1,286
| -26% | -$137K | ﹤0.01% | 787 |
|
|
2023
Q1 | $1.5M | Sell |
5,018
-4,801
| -49% | -$1.43M | 0.01% | 425 |
|
|
2022
Q4 | $3.38M | Buy |
9,819
+3,035
| +45% | +$1.04M | 0.03% | 299 |
|
|
2022
Q3 | $1.28M | Buy |
6,784
+1,430
| +27% | +$270K | 0.01% | 429 |
|
|
2022
Q2 | $1.13M | Buy |
5,354
+3,249
| +154% | +$686K | 0.01% | 459 |
|
|
2022
Q1 | $704K | Sell |
2,105
-63
| -3% | -$21.1K | ﹤0.01% | 626 |
|
|
2021
Q4 | $705K | Buy |
2,168
+757
| +54% | +$246K | ﹤0.01% | 645 |
|
|
2021
Q3 | $685K | Buy |
1,411
+541
| +62% | +$263K | ﹤0.01% | 636 |
|
|
2021
Q2 | $405K | Sell |
870
-639
| -42% | -$297K | ﹤0.01% | 709 |
|
|
2021
Q1 | $1.04M | Buy |
1,509
+1,065
| +240% | +$735K | 0.01% | 387 |
|
|
2020
Q4 | $328K | Buy |
+444
| New | +$328K | ﹤0.01% | 622 |
|